Bruker (NASDAQ:BRKR – Get Free Report) had its price target lowered by stock analysts at Barclays from $69.00 to $65.00 in a research note issued on Monday,Benzinga reports. The firm currently has an ...

Barclays analyst Luke Sergott lowered the firm’s price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm ...

In a report released today, Brandon Couillard from Wells Fargo maintained a Buy rating on Bruker (BRKR – Research Report), with a price target ...

Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before ...

Bruker’s BRKR strong growth reflects its fundamental commitment to innovate high-value solutions and its ongoing portfolio transformation. Yet, the company’s operations face the wrath of excessive ...

Shares of companies in the lab-tool equipment sector, including Bruker (NASDAQ:BRKR), Illumina (NASDAQ:ILMN), Quanterix ...

Bruker's minispec Whole Body Composition Analyzer based on TD-NMR provides a precise method for measurement of lean tissue, fat and fluid in living mice and rats. This body composition analyzer ...

timsTOF was engineered by Bruker experts as an open platform to accelerate the adoption of ion mobility-mass spectrometry analysis across research applications. All that is missing are your ...

Bruker Corporation today announced the launch of the VERTEX NEO Platform today with its first product, the VERTEX NEO R. This ...

Bruker Corporation (NASDAQ: BRKR) is undervalued, trading below its fair value of $74, offering significant upside potential due to its strategic acquisitions and improving book value per share.